OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users

Substrates for the Organic Cation Transporter 1, encoded by the SLC22A1 gene, are metformin, amantadine, pramipexole, and, possibly, levodopa. Recently, we identified that the rs622342 A > C polymorphism is associated with the HbA1c lowering effect in metformin users. In the Rotterdam Study, we a...

Descripción completa

Detalles Bibliográficos
Autores principales: Becker, Matthijs L., Visser, Loes E., van Schaik, Ron H. N., Hofman, Albert, Uitterlinden, André G., Stricker, Bruno H. Ch.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3029819/
https://www.ncbi.nlm.nih.gov/pubmed/20680652
http://dx.doi.org/10.1007/s10048-010-0254-5
Descripción
Sumario:Substrates for the Organic Cation Transporter 1, encoded by the SLC22A1 gene, are metformin, amantadine, pramipexole, and, possibly, levodopa. Recently, we identified that the rs622342 A > C polymorphism is associated with the HbA1c lowering effect in metformin users. In the Rotterdam Study, we associated this polymorphism with higher prescribed doses of all anti-Parkinsonian drugs. Between the first and fifth prescriptions for levodopa, for each minor rs622342 C allele, the prescribed doses were 0.34 defined daily dose higher (95% CI 0.064, 0.62; p = 0.017). The mortality ratio after start of levodopa therapy was 1.47 times higher (95% CI 1.01, 2.13; p = 0.045).

Ejemplares similares